Clinical Trial Update: Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Mayo Clinic-sponsored Phase 1/2 trial evaluated idasanutlin in combination with ixazomib citrate and dexamethasone in relapsed multiple myeloma (including pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Idasanutlin (Idasanutlin)
• Ixazomib citrate (Ixazomib)

Snippet

Sponsor: Mayo Clinic | Conditions: Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-02